European pharmaceutical companies have stronglycriticised the German Government’s method of pricing medicines which operates by comparing prices in other countries and the prices of generics.

In a statement given by Richard Bergström, the Director-General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) warned that the German Government’s policy of linking prices of new medicines to generics and prices in other countries was being applied in an inflexible and unthoughtful manner and risked having the unintended consequence of putting at risk citizen access to novel treatments.

Mr Bergström particularly drew attention to the price assessment model’s inclusion of Greece within its calculation. EFPIA consider this inappropriatein relation to the special pricing circumstances in operation in Greece at the present time which aimto ensure continued access to medicines by patients during a unique period of Government spending austerity.

More information here